These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38380691)

  • 1. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
    Howard JF; Vu T; Mantegazza R; Kushlaf H; Suzuki S; Wiendl H; Beasley KN; Liao S; Meisel A;
    Muscle Nerve; 2024 May; 69(5):556-565. PubMed ID: 38380691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
    van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
    Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
    Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF;
    J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
    Vu T; Meisel A; Mantegazza R; Annane D; Katsuno M; Aguzzi R; Enayetallah A; Beasley KN; Rampal N; Howard JF
    NEJM Evid; 2022 May; 1(5):EVIDoa2100066. PubMed ID: 38319212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ravulizumab: A Review in Generalised Myasthenia Gravis.
    Kang C
    Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
    Habib AA; Benatar M; Vu T; Meisel A; Attarian S; Katsuno M; Liao S; Beasley KN; Howard JF
    Eur J Neurol; 2024 Dec; 31(12):e16490. PubMed ID: 39373062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
    Katyal N; Govindarajan R; Goyal N; Muley S; Muppidi S
    Front Neurol; 2024; 15():1378080. PubMed ID: 38919970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
    Vu T; Ortiz S; Katsuno M; Annane D; Mantegazza R; Beasley KN; Aguzzi R; Howard JF
    J Neurol; 2023 Jun; 270(6):3129-3137. PubMed ID: 36890354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study.
    Habib AA; Sacconi S; Antonini G; Cortés-Vicente E; Grosskreutz J; Mahuwala ZK; Mantegazza R; Pascuzzi RM; Utsugisawa K; Vissing J; Vu T; Wiendl H; Boehnlein M; Greve B; Woltering F; Bril V
    Ther Adv Neurol Disord; 2024; 17():17562864241273036. PubMed ID: 39297052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis.
    Jia D; Zhang F; Li H; Shen Y; Jin Z; Shi FD; Zhang C
    Aging Dis; 2024 Apr; 15(2):824-830. PubMed ID: 37450932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
    Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
    Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
    Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
    Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    Pane C; Di Stefano V; Cuomo N; Sarnataro A; Vinciguerra C; Bevilacqua L; Brighina F; Rini N; Puorro G; Marsili A; Garibaldi M; Fionda L; Saccà F
    J Neurol; 2024 Sep; 271(9):6209-6219. PubMed ID: 39080054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
    Tokuyasu D; Suzuki S; Uzawa A; Nagane Y; Masuda M; Konno S; Kubota T; Samukawa M; Sugimoto T; Ishizuchi K; Oyama M; Yasuda M; Akamine H; Onishi Y; Suzuki Y; Kawaguchi N; Minami N; Kimura T; Takahashi MP; Murai H; Utsugisawa K
    Ann Clin Transl Neurol; 2024 May; 11(5):1338-1346. PubMed ID: 38572524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
    Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
    Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
    Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
    Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study.
    Vissing J; O'Brien F; Wang JJ; Howard JF
    Muscle Nerve; 2018 Aug; 58(2):E21-E22. PubMed ID: 29684239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.